Modifiedblue cross blue shield - tennesseePolicy G2153

Pancreatic Enzyme Testing for Acute Pancreatitis (Commercial, Bluecare, Medicare Advantage, DSNP) – G2153

Defines coverage criteria and limitations for laboratory measurement of pancreatic enzymes and related biomarkers (serum lipase, amylase, trypsin/trypsinogen/TAP, urinary amylase, CRP, IL-6, IL-8, procalcitonin) in the diagnosis and management of acute pancreatitis for commercial, BlueCare, Medicare Advantage, DSNP members.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyPancreatic Enzyme Testing for Acute Pancreatitis (Commercial, Bluecare, Medicare Advantage, DSNP) – G2153

Policy CodePolicy G2153

Change TypeRemoved amylase from diagnostic coverageevidence update

Effective Date

Next Review Date

Key ActionVerify member benefits and document signs and symptoms of acute pancreatitis to support coverage for serum lipase; do not bill for serum amylase except when ordered for analysis of pancreatic cyst fluid.

SourceLink

POLICY UPDATE CHANGES

Removed amylase from prior coverage criteria; measurement of amylase is no longer allowed for the diagnosis of acute pancreatitis except for analysis of pancreatic cyst fluid.

Updated background, guidelines, recommendations, and evidence-based scientific references.

1Covered Test (primary)

9Not Covered Biomarkers/Scenarios

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Referenced CPT codes

Coverage Summary

This coverage policy (Policy G2153) defines criteria and limitations for laboratory measurement of pancreatic enzymes and related biomarkers for the diagnosis and management of acute pancreatitis across commercial, BlueCare, Medicare Advantage, and DSNP members. The policy stance is mixed: serum lipase measurement is covered for individuals presenting with signs and symptoms of acute pancreatitis when criteria are met, while multiple other enzyme and biomarker measurements are not covered in most situations. The policy was last reviewed on 2025-06-04. Per a material change in the 06/04/2025 update, amylase was removed from diagnostic coverage and is no longer allowed for the diagnosis of acute pancreatitis except when used for analysis of pancreatic cyst fluid.

Policy metadata and quick stats

Policy numberG2153

Policy titlePancreatic Enzyme Testing for Acute Pancreatitis

PayerBlue Cross Blue Shield - Tennessee

StatusMODIFIED

Last review2025-06-04

Effective date

Covered Test (primary)1

Not Covered Biomarkers/Scenarios9

Referenced CPT codes7

Medical Necessity / Coverage Criteria

Medically Necessary / Meets Coverage Criteria

Covered when ALL of the following are met:

ALL of the following

Individual presenting with signs and symptoms of acute pancreatitis (see Note 1 for symptom list)
See Note 1: Signs and symptoms include: mild to severe epigastric pain (may radiate to the back), nausea, vomiting, epigastric tenderness, abdominal distention, hypoactive bowel sounds, fever, rapid pulse, tachypnea, hypoxemia, hypotension, anorexia, diarrhea, Cullen sign, Grey Turner sign.
Measurement of serum lipase

Not Medically Necessary / Does Not Meet Coverage Criteria

The following measurements do NOT meet coverage criteria:

Any of the following

Coding

Referenced CPT/HCPCS codes related to pancreatic enzyme and biomarker testingCPT

83690	Lipase
82150	Amylase (Note: measurement of serum amylase is not covered when ordered for anything other than analysis of pancreatic cyst fluid)
86140	C-reactive protein (CRP)
83529	Interleukin-6 (IL-6)
84145	Procalcitonin (PCT)
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified

Provider Actions & Billing Rules

Prior Authorization

Coverage depends on individual benefit

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request; providers must verify member benefits and any Medicare/Medicaid local or national coverage determinations that may supersede this policy.

Billing Rule

Lipase testing frequency limitation

Do not bill for measurement of serum lipase more than once per visit (claims may be denied if billed more than once per visit).

83690
Do not bill more than once per visit; claims may be denied

Background, Evidence & Definitions

Pancreatitis is inflammation of pancreatic tissue; pancreatic enzymes (including amylase, lipase, and trypsinogen) are used to assess pancreatic health because elevations can indicate pancreatic injury and depressed levels relate to exocrine pancreatic insufficiency. Biomarkers such as serum lipase are used diagnostically, while others (trypsin/trypsinogen/TAP, CRP, IL-6, IL-8, procalcitonin, urinary amylase) are discussed but noted as not meeting coverage due to limited evidence. The policy references multiple clinical guidelines and literature (including American College of Gastroenterology, AGA, IAP/APA guidelines, and systematic reviews) to support testing recommendations. A literature review completed through 06/04/2025 prompted updates to background, guidelines, and coverage — specifically removing amylase from diagnostic coverage and updating recommendations and evidence-based references.

Revision date evidence update: Literature review through 06/04/2025 prompted removal of amylase from diagnostic coverage.

Term	Definition
Signs and symptoms of acute pancreatitis (Note 1)	Includes epigastric pain (may radiate to back), nausea, vomiting, epigastric tenderness, abdominal distention, hypoactive bowel sounds, fever, rapid pulse, tachypnea, hypoxemia, hypotension, anorexia, diarrhea, Cullen sign, Grey Turner sign.

Revision History

2025-06-04material_changeLatest

Amylase removed from prior coverage criteria; measurement of amylase is no longer allowed for the diagnosis of acute pancreatitis except for analysis of pancreatic cyst fluid.

2025-06-04literature_review_update

Updated background, guidelines, recommendations, and evidence-based scientific references.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyPancreatic Enzyme Testing for Acute Pancreatitis (Commercial, Bluecare, Medicare Advantage, DSNP) – G2153

Policy CodePolicy G2153

Change TypeRemoved amylase from diagnostic coverageevidence update

Effective Date

Next Review Date

SourceLink

On This Page

Measurement of serum lipase for individuals with an established diagnosis of acute or chronic pancreatitis

lipase not covered for monitoring established pancreatitis

Measurement of serum lipase more than once per visit

repeat lipase testing per visit is not covered

Measurement of serum lipase for asymptomatic individuals during a general exam without abnormal findings

Measurement of serum amylase when ordered for anything other than analysis of pancreatic cyst fluid

Amylase is not covered except for pancreatic cyst fluid analysis

Measurement of serum or urine trypsin/trypsinogen/TAP (trypsinogen activation peptide) for diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis

Measurement of C-reactive protein (CRP) for diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis

Measurement of Interleukin-6 (IL-6) for diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis

Measurement of Interleukin-8 (IL-8) for diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis

Measurement of procalcitonin for diagnosis, assessment, prognosis, and/or determination of severity of acute pancreatitis

Measurement of urinary amylase concentration for the initial diagnosis of acute pancreatitis in individuals presenting with signs and symptoms of acute pancreatitis

Measurement of serum lipase for all other situations or conditions not described as covered above

Documentation Required

Symptom documentation for lipase coverage

Document signs and symptoms of acute pancreatitis (see Note 1 symptom list) to support coverage for serum lipase testing.

Billing Rule

Amylase testing restricted

Do not bill for serum amylase (82150) except when ordered for analysis of pancreatic cyst fluid; other uses are not covered and may be denied.

82150
Only allowed for pancreatic cyst fluid analysis; other uses not covered and may be denied

Billing Rule

Other biomarkers not covered

Do not bill for CRP (86140), IL-6 (83529), IL-8 (listed under immunoassay codes), or procalcitonin (84145) when ordered for diagnosis, assessment, prognosis, or severity determination of acute pancreatitis; these are not covered for those purposes.

86140
83529
84145
Do not bill for CRP, IL-6, IL-8, or procalcitonin for diagnosis, assessment, prognosis, or severity determination of acute pancreatitis